In the current study, we show for the first time that DSRCT tumor tissue shows a high level of PARP1 and SLFN11 expression, that DSRCT cells have a similar sensitivity profile to the PARP inhibitor olaparib as previously observed in ES cells and that combination treatment of olaparib with the alkylating agent TMZ leads to drug synergy and enhanced antitumor effects in vitro and in vivo. The gene discussed is PARP1; the disease is neoplasm.